SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories - Quaterly Results

13 Nov 2021 Evaluate
The September 2021 quarter revenue stood at Rs. 14238.40 millions, up 9.71% as compared to Rs. 12977.70 millions during the corresponding quarter last year.A slender decline of -6.54% was recorded to Rs. 2576.40  millions from Rs. 2756.80 millions in the corresponding previous quarter.A decline of 3740.90 millions was observed in the OP in the quarter ended September 2021 from 3751.60 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 14238.40 12977.70 9.71 29024.40 27830.20 4.29 51391.60 43674.30 17.67
Other Income 150.70 150.00 0.47 286.80 266.80 7.50 622.40 646.90 -3.79
PBIDT 3740.90 3751.60 -0.29 7816.80 9747.90 -19.81 15758.20 9794.50 60.89
Interest 14.70 18.10 -18.78 27.30 42.70 -36.07 81.40 157.90 -48.45
PBDT 3726.20 3733.50 -0.20 7789.50 9705.20 -19.74 15676.80 9636.60 62.68
Depreciation 505.00 462.60 9.17 1004.60 914.90 9.80 1877.20 1786.90 5.05
PBT 3221.20 3270.90 -1.52 6784.90 8790.30 -22.81 13799.60 7849.70 75.80
TAX 644.80 514.10 25.42 1361.30 1497.10 -9.07 2391.90 1325.10 80.51
Deferred Tax 83.00 -6.90 -1302.90 174.50 -38.90 -548.59 -57.90 -54.70 5.85
PAT 2576.40 2756.80 -6.54 5423.60 7293.20 -25.63 11407.70 6524.60 74.84
Equity 253.70 253.70 0.00 253.70 253.70 0.00 253.70 252.70 0.40
PBIDTM(%) 26.27 28.91 -9.11 26.93 35.03 -23.11 30.66 22.43 36.73

Ipca Laboratories Share Price

1551.75 -6.15 (-0.39%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×